Heart failure and inflammation-related biomarkers as predictors of new onset diabetes in the general population

Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis : 24-month safety and efficacy in subgroup of patients with cardiac involvement